IQVIA Holdings Inc. (NYSE:IQV) Receives Average Recommendation of “Moderate Buy” from Analysts

IQVIA Holdings Inc. (NYSE:IQV) has earned a consensus recommendation of “Moderate Buy” from the nineteen brokerages that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $259.13.

Several research analysts have weighed in on IQV shares. BTIG Research cut their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Argus upgraded shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Barclays reduced their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, The Goldman Sachs Group lowered their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st.

IQVIA Price Performance

IQVIA stock opened at $191.19 on Tuesday. IQVIA has a 52 week low of $187.62 and a 52 week high of $261.73. The company’s 50 day moving average price is $225.96 and its two-hundred day moving average price is $228.02. The stock has a market cap of $34.70 billion, a P/E ratio of 25.09, a P/E/G ratio of 1.98 and a beta of 1.51. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 6.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Capital Performance Advisors LLP purchased a new position in shares of IQVIA in the 3rd quarter worth about $27,000. Park Place Capital Corp bought a new position in IQVIA during the third quarter valued at approximately $28,000. Versant Capital Management Inc raised its stake in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in shares of IQVIA in the 2nd quarter valued at $27,000. Finally, Itau Unibanco Holding S.A. bought a new position in shares of IQVIA during the 2nd quarter valued at $29,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.